白宫已正式撤回对海蒂·奥弗顿(Heidi Overton)担任美国食品药品监督管理局(FDA)局长的提名 12345。这一决定发生在参议院卫生委员会举行关键确认投票的前一天 1。该提名由唐纳德·特朗普于八月提出,被视为在首任局长马蒂·马卡里(Marty Makary)动荡任期后寻求机构稳定的举措 1。一位白宫官员向《卫报》透露了这一消息 1。
多家媒体报道指出,奥弗顿因缺乏足够支持而被撤换 2。具体而言,她难以获得足够的共和党参议员支持以确保通过确认程序 4,且两党对其提名均存在反对声浪 2。此外,她与卫生与公众服务部部长小罗伯特·肯尼迪(RFK Jr.)之间被描述为“冰冷”的紧张关系也是导致撤回的因素之一 34。
针对白宫的这一举动,路易斯安那州共和党参议员比尔·卡西迪表达了强烈批评 5。卡西迪声称奥弗顿原本“很可能已获得足够选票”,并指责白宫此举源于参议院共和党内部支持态度的摇摆不定 5。
The White House has officially withdrawn the nomination of Dr. Heidi Overton to lead the U.S. Food and Drug Administration (FDA). 12345 The decision was made on the eve of a critical vote by the Senate Health Committee, according to reports citing a White House official who spoke to The Guardian. 12 This move marks the end of the confirmation process for Overton, who had been nominated in August by President Donald Trump to replace former Commissioner Marty Makary following his turbulent tenure. 1
Several factors contributed to the withdrawal, primarily centered on insufficient legislative support. 24 Sources indicate that Overton struggled to secure the necessary votes from Republican senators to ensure her confirmation. 45 While some reports cited bipartisan pushback as the reason for lacking support, others noted specifically that she failed to win sufficient GOP backing. 24 Additionally, multiple outlets cited an "icy" relationship between Overton and Robert F. Kennedy Jr., the nominee for Secretary of Health and Human Services, as a complicating factor in her bid for leadership at the FDA. 34
Senator Bill Cassidy of Louisiana, a Republican, criticized the White House’s decision to pull the nomination. 5 Cassidy argued that Overton "probably had the votes" required for confirmation, suggesting that the administration acted prematurely despite her potential viability within the Senate. 5
评论
还没有评论,欢迎留下第一条。